• Explore /
  • Poster
  • / SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).

SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Abstract Poster

Authors

Eric Small

Eric Jay Small

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Eric Jay Small , Fred Saad , Simon Chowdhury , Boris A. Hadaschik , Julie Nicole Graff , David Olmos , Paul N. Mainwaring , Hiroji Uemura , Angela Lopez-Gitlitz , Geralyn Carol Trudel , Byron M. Espina , Youyi Shu , Youn C. Park , Wayne R. Rackoff , Margaret K. Yu , Matthew Raymond Smith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01946204

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 161)

DOI

10.1200/JCO.2018.36.6_suppl.161

Abstract #

161

Poster Bd #

A5

Abstract Disclosures

Similar Posters

First Author: Eric Jay Small

First Author: Tomasz M. Beer

First Author: Tomasz M. Beer

First Author: Richard Gagnon